^
Association details:
| Biomarker: | DEK-AFF2 fusion |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Excerpt:
...confirmed the presence of the DEK-AFF2 fusion with RNA-seq...Six months after the last chemotherapy treatment, the patient began treatment with an anti-PD-1 antibody (Pembrolizumab), which induced a radiographic response after 5 months, and complete regression of disease by 8 months (Fig. 1b). The patient was treated for an additional year, completed treatment at 20 months, and remains disease-free at 29 months.
DOI:
10.1038/s41591-019-0434-2
